Overview

• An analysis of more than 90,000 obese patients with type 2 diabetes and HFpEF found semaglutide was associated with a 42% lower one-year risk of heart‑failure hospitalization or death and tirzepatide with a 58% lower risk versus sitagliptin, according to JAMA and ESC presentations.
• In the U.S. claims–based study emulating prior trials, researchers also reported a head‑to‑head comparison in 28,100 patients that showed no meaningful benefit of tirzepatide over semaglutide for HFpEF outcomes.
• Novo Nordisk’s STEER real‑world analysis reported that, during continuous treatment without gaps, Wegovy produced a 57% greater reduction in heart attack, stroke, or cardiovascular‑related death (or death from any cause) compared with tirzepatide in people with overweight or obesity and cardiovascular disease but no diabetes.
• Across all treated patients in STEER, Wegovy users saw a 29% lower risk of major cardiovascular events and death than tirzepatide users, though absolute event numbers were low and follow‑up averaged only a few months.
• Cardiology leaders welcomed the signals of benefit for GLP‑1–based therapies in HFpEF but stressed that the observational designs and limited follow‑up mean causality is unproven and guideline changes should await randomized outcome trials.